Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Annalisa D'Andrea is active.

Publication


Featured researches published by Annalisa D'Andrea.


Nature | 1998

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.

Veronique M. Braud; David S. J. Allan; Christopher A. O'Callaghan; Kalle Söderström; Annalisa D'Andrea; Graham S. Ogg; Sasha Lazetic; Neil T. Young; John I. Bell; Joseph H. Phillips; Lewis L. Lanier; Andrew J. McMichael

The protein HLA-E is a non-classical major histocompatibility complex (MHC) molecule of limited sequence variability. Its expression on the cell surface is regulated by the binding of peptides derived from the signal sequence of some other MHC class I molecules,. Here we report the identification of ligands for HLA-E. We constructed tetramers in which recombinant HLA-E and β2-microglobulin were refolded with an MHC leader-sequence peptide, biotinylated, and conjugated to phycoerythrin-labelled Extravidin. This HLA-E tetramer bound to natural killer (NK) cells and a small subset of T cells from peripheral blood. On transfectants, the tetramer bound to the CD94/NKG2A, CD94/NKGK2B and CD94/NKG2C NK cell receptors, but did not bind to the immunoglobulin family of NK cell receptors (KIR). Surface expression of HLA-E was enough to protect target cells from lysis by CD94/NKG2A+ NK-cell clones. A subset of HLA class I alleles has been shown to inhibit killing by CD94/NKG2A+ NK-cell clones. Only the HLA alleles that possess a leader peptide capable of upregulating HLA-E surface expression confer resistance to NK-cell-mediated lysis, implying that their action is mediated by HLA-E, the predominant ligand for the NK cell inhibitory receptor CD94/NKG2A.


Immunity | 1997

Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.

Nicholas M. Valiante; Markus Uhrberg; Heather G. Shilling; Kristin Lienert-Weidenbach; Kelly L. Arnett; Annalisa D'Andrea; Joseph H. Phillips; Lewis L. Lanier; Peter Parham

The expression of KIR and CD94:NKG2 receptors was determined for more than 100 natural killer (NK) cell clones obtained from two blood donors who differ in their HLA class I and KIR genes. More than 98% of the clones were inhibited by individual autologous class I allotypes, and every clone was inhibited by the combination of autologous allotypes. The patterns of inhibition correlate with expression of inhibitory receptors of defined specificity. One donor possesses three class I ligands for KIR, and a majority of NK cells use KIR as their inhibitory receptor; the second donor possesses only a single ligand for KIR, and a majority of NK cells use the more broadly reactive CD94:NKG2a as their inhibitory receptor. Because of these differences, the first donor has subpopulations of NK cells that kill cells of the second donor, whereas the NK cells of the second donor are universally tolerant of cells from the first donor.


Journal of Experimental Medicine | 2002

Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein

Stefania Crotta; Annalisa Stilla; Andreas Wack; Annalisa D'Andrea; Sandra Nuti; Ugo D'Oro; Marta Mosca; Franco Filliponi; R. Maurizia Brunetto; Sergio Abrignani; Nicholas M. Valiante

The immune response against hepatitis C virus (HCV) is rarely effective at clearing the virus, resulting in ∼170 million chronic HCV infections worldwide. Here we report that ligation of an HCV receptor (CD81) inhibits natural killer (NK) cells. Cross-linking of CD81 by the major envelope protein of HCV (HCV-E2) or anti-CD81 antibodies blocks NK cell activation, cytokine production, cytotoxic granule release, and proliferation. This inhibitory effect was observed using both activated and resting NK cells. Conversely, on NK-like T cell clones, including those expressing NK cell inhibitory receptors, CD81 ligation delivered a costimulatory signal. Engagement of CD81 on NK cells blocks tyrosine phosphorylation through a mechanism which is distinct from the negative signaling pathways associated with NK cell inhibitory receptors for major histocompatibility complex class I. These results implicate HCV-E2–mediated inhibition of NK cells as an efficient HCV evasion strategy targeting the early antiviral activities of NK cells and allowing the virus to establish itself as a chronic infection.


Proceedings of the National Academy of Sciences of the United States of America | 2009

Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component

Barry R. O'Keefe; Fakhrieh S. Vojdani; Viviana Buffa; Robin J. Shattock; David C. Montefiori; James Bakke; Jon C. Mirsalis; Annalisa D'Andrea; Steven D. Hume; Barry Bratcher; Carrie J. Saucedo; James B. McMahon; Gregory P. Pogue; Kenneth E. Palmer

To prevent sexually transmitted HIV, the most desirable active ingredients of microbicides are antiretrovirals (ARVs) that directly target viral entry and avert infection at mucosal surfaces. However, most promising ARV entry inhibitors are biologicals, which are costly to manufacture and deliver to resource-poor areas where effective microbicides are urgently needed. Here, we report a manufacturing breakthrough for griffithsin (GRFT), one of the most potent HIV entry inhibitors. This red algal protein was produced in multigram quantities after extraction from Nicotiana benthamiana plants transduced with a tobacco mosaic virus vector expressing GRFT. Plant-produced GRFT (GRFT-P) was shown as active against HIV at picomolar concentrations, directly virucidal via binding to HIV envelope glycoproteins, and capable of blocking cell-to-cell HIV transmission. GRFT-P has broad-spectrum activity against HIV clades A, B, and C, with utility as a microbicide component for HIV prevention in established epidemics in sub-Saharan Africa, South Asia, China, and the industrialized West. Cognizant of the imperative that microbicides not induce epithelial damage or inflammatory responses, we also show that GRFT-P is nonirritating and noninflammatory in human cervical explants and in vivo in the rabbit vaginal irritation model. Moreover, GRFT-P is potently active in preventing infection of cervical explants by HIV-1 and has no mitogenic activity on cultured human lymphocytes.


Progress in Growth Factor Research | 1992

Natural Killer cell Stimulatory Factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation

Giorgio Trinchieri; Maria Wysocka; Annalisa D'Andrea; Manthrasalam Rengaraju; Miguel Aste-Amezaga; Marek Kubin; Nicholas M. Valiante; Jihed Chehimi

Natural Killer cell Stimulatory Factor (NKSF) or interleukin-12 (IL-12) is a heterodimeric cytokine of 70 kDa formed by a heavy chain of 40 kDa (p40) and a light chain of 35 kDa (p35). Although it was originally identified and purified from the supernatant of Epstein-Barr virus-transformed B cell lines, it has been shown that among peripheral blood cells NKSF/IL-12 is predominantly produced by monocytes, with lower production by B cells and other accessory cells. The most powerful inducers of NKSF/IL-12 production are bacteria, bacterial products and parasites. In addition to the biologically active p70 heterodimer, the cells producing NKSF/IL-12 also secrete a large excess of monomeric p40, a molecule with no demonstrable biological activity. NKSF/IL-12 is active on T lymphocytes and NK cells on which it induces production of lymphokines, enhancement of cytotoxic activity and mitogenic effects. NKSF/IL-12 induces T and NK cells to produce IFN-gamma and synergizes with other IFN-gamma inducers in this effect. In vitro, and probably in vivo, NKSF/IL-12 is required for optimal IFN-gamma production. When human lymphocytes are stimulated with antigens in vitro, addition of exogenous NKSF/IL-12 to the culture induces differentiation of T helper type 1 (Th1) cells, whereas neutralization of endogenous NKSF/IL-12 with antibodies favors differentiation of Th2 cells. IFN-gamma, a product of Th1 cells, enhances NKSF/IL-12 production by mononuclear cells, whereas IL-10 and IL-4, products of Th2 cells, efficiently inhibit it. Therefore, NKSF/IL-12 appears to be an important inducer of Th1 responses produced by accessory cells during early antigenic stimulation and its production is regulated by a positive feedback mechanism mediated by Th1 cells through IFN-gamma and a negative one by Th2 cells through IL-10 and IL-4. The balance of IL-12 production versus IL-10 and IL-4 production early during an immune response might therefore be instrumental in determining Th1-type versus Th2-type immune responses. Because of this potential role of IL-12 during immune responses, our results demonstrating the impaired ability of HIV seropositive patients to produce NKSF/IL-12 in response to bacterial stimulation suggest that this defect in NKSF/IL-12 production might be a factor contributing to their immune depression.


European Journal of Immunology | 2000

Neonatal invariant Vα24+ NKT lymphocytes are activated memory cells

Annalisa D'Andrea; Delphine Goux; Claudia de Lalla; Yasuhiko Koezuka; Daniela Montagna; Antonia Moretta; Paolo Dellabona; Giulia Casorati; Sergio Abrignani

NKT cells are a small subset of T lymphocytes which express an invariant Vα24JαQ TCR and recognize glycolipids presented by CD1d. In adults, NKT cells have a memory phenotype, frequently associated with oligoclonal expansion, express NK cell markers, and produce T0 cytokines upon primary stimulation. Because of these features, NKT cells are regarded as lymphocytes of innate immunity. We investigated NKT cells from cord blood to see how these cells appear in the absence of exogenous stimuli. We found that NKT cells are present at comparable frequencies in cord blood and adult peripheral blood mononuclear cells and in both cases display a memory (CD45RO+CD62L–) phenotype. However, neonatal NKT cells differ from their adult counterparts by the following characteristics: (1) they express markers of activation, such as CD25; (2) they are polyclonal; (3) they do not produce cytokines in response to primary stimulation. Together, our data show that human NKT cells arise in the newborn with an activated memory phenotype, probably due to recognition of an endogenous ligand(s). The absence of oligoclonal expansion and primary effector functions also suggest that neonatal NKT cells, despite their activated memory phenotype, require a further priming / differentiation event to behave as fully functional cells of innate immunity.


Immunological Reviews | 2000

Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C.

Nicholas M. Valiante; Annalisa D'Andrea; Stefania Crotta; Franziska Lechner; Paul Klenerman; Sandra Nuti; Andreas Wack; Sergio Abrignani

Summary: The healthy liver of adult humans has little or no lymphocyte component and the histological finding of intrahepatic lymphocytes (IHL) is evidence of liver pathology. In a liver injured by chronic hepatitis C, the most common chronic liver disease, most IHL are activated/pro‐inflammatory cells, which are particularly enriched for effectors of innate immunity (natural killer (NK), natural T, and other NK‐like T cells). IHL do not undergo clonal expansion in the liver but migrate from extrahepatic sites to the chronically infected liver, where they display effector function and subsequently die, suggesting that maintenance of the IHL pool depends on continuous lymphocyte migration. The cytotoxic and inflammatory functions of these IHL have three potential outcomes: 1) they could be helpful in clearing the virus (a rare case in hepatitis C virus (HCV) infection); 2) they could be useless and have no effect on the infection; or 3) they could be harmful, whereby overaggressive lymphocyte responses destroy the liver in a continuous and unsuccessful attempt to clear the virus. Unfortunately, we do not know as of yet which of these possibilities is the case and, therefore, a more complete picture of the intrahepatic immune response will be relevant to the development of new therapeutic strategies against HCV. Additionally and from a more general perspective, due to the availability of biopsied material and the high prevalence (~3%) of HCV infection worldwide, studying the chronically inflamed liver of hepatitis C patients is an ideal model to investigate the poorly understood processes of lymphocyte trafficking, activation and death to non‐lymphoid sites of chronic inflammation in man.


Current Topics in Microbiology and Immunology | 1998

Killer cell inhibitory receptor expression by T cells.

Annalisa D'Andrea; Lewis L. Lanier

The killer cell inhibitory receptors (KIR) are a family of immunoglobulin (Ig)-like cell surface receptors which are differentially expressed by cytotoxic lymphocyte populations and recognize subsets of human leukocyte antigen (HLA) class I molecules on potential target cells (Long et al. 1996). Originally identified as inhibitory receptors of natural killer (NK) cells having discrete specificities for HLA class I allotypes, KIR are also expressed by a small but significant population of T cells (Ferrini et al. 1994; Mingari et al. 1995; Phillips et al. 1995). Importantly, KIR recognition of their complementary class I ligands can modulate T cell function in a manner comparable to that observed for NK cells. This contribution summarizes recent advances in understanding the functional significance of T cell expression of KIR family members.


Journal of Experimental Medicine | 1993

Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells.

Annalisa D'Andrea; Miguel Aste-Amezaga; Nicholas M. Valiante; Xiaojing Ma; Marek Kubin; Giorgio Trinchieri


Journal of Experimental Medicine | 1994

Impaired interleukin 12 production in human immunodeficiency virus-infected patients.

Jihed Chehimi; Stuart E. Starr; Ian Frank; Annalisa D'Andrea; Xiaojing Ma; R R MacGregor; J Sennelier; Giorgio Trinchieri

Collaboration


Dive into the Annalisa D'Andrea's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jihed Chehimi

Children's Hospital of Philadelphia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge